BKA
DGX icon

Brick & Kyle Associates’s Quest Diagnostics DGX Stock Holding History

Brick & Kyle Associates’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-400
Closed -$39K – 152
2017
Q1 		$39K Hold
400
– – 0.03% 202
2016
Q4 		$37K Hold
400
– – 0.03% 206
2016
Q3 		$34K Hold
400
– – 0.03% 214
2016
Q2 		$33K Hold
400
– – 0.03% 208
2016
Q1 		$29K Hold
400
– – 0.03% 218
2015
Q4 		$28K Hold
400
– – 0.02% 211
2015
Q3 		$25K Hold
400
– – 0.02% 228
2015
Q2 		$29K Hold
400
– – 0.02% 230
2015
Q1 		$31K Hold
400
– – 0.03% 226
2014
Q4 		$27K Buy
+400
New +$25.2K 0.02% 228

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Brick & Kyle Associates's DGX Position: Q2 2017 in Review

Brick & Kyle Associates sold out of Quest Diagnostics (DGX) in Q2 2017, closing a stake of 400 shares — an estimated $39K sold.

Brick & Kyle Associates first reported a position in DGX in Q4 2014 and held it in 10 quarters. The position peaked at $39K in Q1 2017. 643 funds tracked by Wall St. Rank hold DGX as of Q2 2017.

  • Brick & Kyle Associates reported no remaining Quest Diagnostics position as of Q2 2017 after selling out during the quarter.
  • Brick & Kyle Associates sold 400 Quest Diagnostics shares in Q2 2017, an estimated $39K.
  • Brick & Kyle Associates first reported a position in Quest Diagnostics in Q4 2014 and held it in 10 quarters.
  • Brick & Kyle Associates's Quest Diagnostics position peaked at $39K in Q1 2017.
  • 643 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2017.

Based on Brick & Kyle Associates's 13F filing for Q2 2017, filed 14 Aug 2017.